

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

Delphion

RESEARCH
INTEGRATED IAM
SERVICES
INSIDE DELPHION

Log Out
Work Files
Saved Searches

My Account
Products
News
Events

Search: Quick/Number Boolean Advanced

## The Delphion Integrated View

**Buy Now:** [More choices...](#)

**Tools:** Add to Work File: [Create new Work File](#)

**View:** [INPADOC](#) | **Jump to:**  ☒

**Go to:** [Derwent...](#)

☒ [Email](#)

ⓘ **Title:** **JP8165248A2: ENDOTOXIN-DERIVED INFLAMMATION INHIBITOR**

ⓘ **Country:** JP Japan

ⓘ **Kind:** A

ⓘ **Inventor:** KURIWA NOBUO;

ⓘ **Assignee:** KURIWA NOBUO  
[News, Profiles, Stocks and More about this company](#)


ⓘ **Published / Filed:** June 25, 1996 / Dec. 15, 1994

ⓘ **Application Number:** JP1994000311963

ⓘ **IPC Code:** A61K 38/16; A61K 38/00;

ⓘ **Priority Number:** Dec. 15, 1994 JP1994000311963

ⓘ **Abstract:**




**PURPOSE:** To provide a new inflammation inhibitor capable of inhibiting endotoxin-inducible cytokine release, containing, as active ingredient, a lactoferrin-derived specific peptide.

**CONSTITUTION:** This inflammation inhibitor contains, as active ingredient, a peptide  $\leq 10000$  dalton in molecular weight derived from the N-terminal domain of lactoferrin. The peptide, which presents action to inhibit endotoxin-inducible cytokine release from immunocytes (for example, to inhibit interleukin-6 release from human monocytes due to endotoxin stimulation), has effect at concentrations of as low as 0.5-50ppm. Therefore, this inhibitor is useful for preventing and treating harmful effects due to endotoxin such as acute inflammation and septicemia, mediated by cytokine, due to Gram-negative bacteria. The peptide is obtained by hydrolysis of lactoferrin or by conventional peptide synthetic process, and purified. This inhibitor can be used in the form of oral agent, injection, eye drop or spray, or quasi-drug (e.g. mouthwash), cosmetic, food (e.g. chewing gum), etc.

**COPYRIGHT:** (C)1996,JPO

ⓘ **Family:** None

ⓘ **Other Abstract Info:** CHEMABS 125(15)185855Y CAN125(15)185855Y DERABS C96-350155 DERC96-350155



[this for the Gallery...](#)